IBD

The Role of Biosimilars in Inflammatory Bowel Disease

Sudarshan Paramsothy, MD, Noa Krugliak Cleveland, MD, Nada Zmeter, MD, and David T. Rubin, MD

  Abstract: Monoclonal antibody biologic therapies, introduced nearly 20 years ago, revolutionized the treatment of inflammatory bowel disease (IBD) and are now well established as the […]

Hepatology

Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials

William N. Hannah, Jr, MD, Dawn M. Torres, MD, and Stephen A. Harrison, MD

  Abstract: Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease in developed countries, and the rates of NAFLD continue to rise […]

Advances in GERD

Esophageal Cancer Prevention

Gastroenterology & Hepatology Volume 12, Issue 12, December 2016 Kenneth K. Wang, MD Director, Advanced Endoscopy Group and Esophageal Neoplasia Clinic Consultant, Division of Gastroenterology and […]

Advances in Hepatology

The Possible Association Between DAA Treatment for HCV Infection and HCC Recurrence

Gastroenterology & Hepatology Volume 12, Issue 12, December 2016 Robert S. Brown, Jr, MD, MPH Gladys and Roland Harriman Professor of Medicine Clinical Chief, Division of […]

IBD

Inhibition of Interleukin-12 and/or -23 for the Treatment of Inflammatory Bowel Disease

Bruce E. Sands, MD

  G&H  Which agents have been evaluated for inhibiting interleukin-12 and/or -23 for the treatment of inflammatory bowel disease? BS  A handful of agents have been, […]

HCC

Liver Transplant and Hepatocellular Carcinoma

Robert Wong, MD, MS

  G&H  How are donor livers currently allocated to patients in need of a transplant? RW  The current allocation system for patients with chronic liver disease […]

Endoscopy

Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Gastroenterology & Hepatology Volume 12, Issue 12, December 2016 Vikesh K. Singh, MD, MSc Director, Pancreatitis Center Medical Director, Pancreatic Islet Autotransplantation Program Associate Professor of […]

Letter From the Editor

Letter From the Editor: Biosimilars in Inflammatory Bowel Disease

Gastroenterology & Hepatology Volume 12, Issue 12, December 2016 Are biosimilars the future of inflammatory bowel disease (IBD) management? Biologic agents are widely considered to be […]